Trials / Unknown
UnknownNCT02409199
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared to docetaxel treatment in patients with advanced gastric cancer. At the start of the trial, patients will be randomized to one treatment arm: Arm A: apatinib 850mg qd every 3 weeks; Arm B: docetaxel 60mg/m2 every 3 weeks. Tumor assessment will be done every 8 weeks according to RECIST 1.1. The primary endpoint is progression free survival (PFS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | |
| DRUG | apatinib |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-12-01
- Completion
- 2017-03-01
- First posted
- 2015-04-06
- Last updated
- 2015-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02409199. Inclusion in this directory is not an endorsement.